The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.
Medscape Medical News
New FDA Approval Expands Use of Cemiplimab in NSCLC
The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.
Medscape Medical News
